GVR Report cover In Situ Hybridization Market Size, Share & Trends Report

In Situ Hybridization Market Size, Share & Trends Analysis Report By Technology (FISH, CISH), By Probe Type (DNA, RNA), By Product, By Application, By End-user (CROs), By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-2-68038-109-2
  • Number of Pages: 117
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Report Overview

The global in situ hybridization market size was valued at USD 1,333.5 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.9% from 2021 to 2028. Increasing prevalence of target disorders, increasing investments in in-vitro diagnostics space, and technological advancements in in situ hybridization (ISH) are some key driving factors for market growth.

Canada in-situ hybridization market size, by application, 2018 - 2028 (USD Million)

The COVID-19 pandemic also served as a driving factor for the ISH market growth. In June 2021, The University of Oxford collaborated with the University of Warwick to research a method to detect the COVID-19 virus in 20 minutes using in situ hybridization. This technology is previously used to detect pathogens inside cells, such as the Epstein-Barr and HIV. Such developments are expected to propel market growth in the near future.

In the past few years, various research institutions and organizations have indulged in thorough R&D for developing a technology to determine the molecular profiles of single cells. For instance, Bio-protocol developed in situ hybridization technique known as Proximity Ligation in situ Hybridization. The technique is considered high performance, low cost, rapid multiplexing, and simple to use.

The affordable in situ hybridization technology increases the accessibility for developing countries, which are highly prone to infections and diseases. Regulatory bodies have launched various policies and initiatives to increase awareness among people. For instance, in August 2021, Federal Capital Territory Public Health Department in Nigeria collaborated with the WHO to spread awareness of infectious diseases.

In recent years, the use of ISH products has expanded, leading to an increasing, number of specialized contract research organizations. This intensified the market competition. For instance, with rigorous legislative requirements and high sample throughput, Reveal Biosciences serves research on tissue and advanced tissue technology services using in situ hybridization and other methods.

Technology Insights

Based on technology, the FISH segment dominated the market for in situ hybridization and accounted for the largest revenue share of 53.9% in 2020. This can be attributed to the wide range of applications such as diagnosing congenital diseases including Edward's Syndrome and Down's Syndrome. The rising incidence and diagnosis of such diseases has increased the utilization of FISH technology and it is expected to expedite segment growth.

The CISH segment also captured a significant share of in situ hybridization over time as it is a cost-effective, reliable, and practical alternative for FISH. The technology aids in detecting HER-2/neu oncogene copies with conventional peroxidase reaction. Rising acceptance of CISH technology for HPV genotyping on cervical smears is further anticipated to boost the ISH market growth throughout the forecast period.

The affordable technological advancements in the ISH market are driving the segment growth. For instance, a group of researchers published their study in May 2021, suggesting that the chromogen-based RNA in situ hybridization approach is an effective method to detect druggable cytokines in atopic dermatitis and psoriasis. Technological advancement increases the scope of the in-situ hybridization and fuels segment growth.

Probe Insights

The DNA probe segment dominated the market for in situ hybridization and accounted for the largest revenue share of 51.1% in 2020. However, the RNA probe showcased a better growth rate in the forecasted period, owing to the development of new nucleic acid-based diagnostic assays and tools for analyzing DNA and RNA molecules.

RNA probe is used to detect the presence of complementary nucleic acid sequences by hybridization. The popularity of RNA as a hybridization tool is increasing owing to several advantages, such as the probes are synthesized by in vitro transcription and can be a replacement for DNA probes in almost all applications. As there is a single-stranded and improved signal than DNA probes, can explain the lucrative CAGR from 2021 to 2028.

The acceleration in the development of probe-based technology and products is anticipated to boost the growth of the ISH market. For instance, in July 2020, US-FDA permitted the Ventana HER2 Dual ISH DNA Probe cocktail assay to detect the HER2 biomarker in breast cancer.

Product Insights

The instruments segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.3% in 2020. The increasing demand for instruments is owing to the raising chains of diagnostic and research laboratories. In addition, an increase in the number of strategic initiatives among the players to expand their product portfolio is anticipated to boost the growth of in situ hybridization.

For instance,, in April 2021, Bio-Techne Corporation announced to introduce RNAscope technology along with new DNA scope assays in the commercial market. It will be utilized to detect the copy number and structure variations of DNA. Such new product launches would supplement the market growth.

On the other hand, the services segment is anticipated to witness significant growth in the market for in situ hybridization. Increasing outsourcing to improve operational functionalities and ensure high adherence to quality standards and is contributing toward the lucrative CAGR of this segment. Owing to this trend, various CROs offer in situ hybridization services under their portfolio.

Application Insights

The cancer segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.4% in 2020. The increase in the incidence rate of cancer cases is anticipated to drive the growth. According to data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With the rise in the number of cancer cases, the need for in situ hybridization techniques for rapid and efficient diagnosis is high.

Rising unhealthy lifestyle, aging population, health conditions, and environment are leading factors for causing cancers. Various organizations initiate research and promote further development in the treatment of cancers. For instance, American Institute for Cancer Research funded approximately USD 110 million under the grant program for cancer research in 2020-21.

End-use Insights

The hospitals and diagnostic laboratories segment dominated the market for in situ hybridization and accounted for the largest revenue share of 48.8% in 2020. There are three major end-users in the market, hospitals and diagnostic laboratories, Contract Research Organizations (CROs), and academic and research institutions.

Global in situ hybridization market share, by end-use, 2020 (%)

The ongoing pandemic can be the key driver for the laboratories as understanding the pathogen can offer a competitive advantage to the laboratories and assist to lead the industry. Likewise, the Contract Research Organizations segment is growing at a faster pace, although the absolute value of revenue is less compared to the other segments.

Many organizations outsource their research and clinical trials to research laboratories and factors such as specialized workforce, deduces the cost for companies, and improving the efficiency can motivate companies and other organizations to outsource their research to the laboratories.

Regional Insights

North America dominated the In Situ Hybridization (ISH) market and accounted for the largest revenue share of 44.9% in 2020. This growth in the region can be attributed to the presence of a considerable number of market players and incentivized research projects by the regional government.

High healthcare expenditure and stringent regulations by FDA andHealth Canada are some other factors contributing to the dominance of the region throughout the forecast period. North American market holds the highest number of patents, whereas Asia Pacific market has a higher marginal increase than other regions. The presence of research projects and institutions supported by Health Canada is likely to boost the market by a minor margin.

In Asia Pacific, the market is likely to witness the fastest growth over the forecast period. Raising the attention of regional authorities in R&D is expected to be the key market driver over the forecast period. China and India are the fastest-growing markets in the Asia Pacific region.

Key Companies & Market Share Insights

The in-situ hybridization market is competitive in nature and some of the key players accounted for the largest market share owing to their extensive product portfolios and geographic presence across the world. Major players are adopting strategies, such as distribution channel enhancement, operational restructuring, and opting for direct contracts with distributors, to reduce their operational expenditure and increase profit margins.

Other companies are adopting strategies such as mergers and acquisitions, distribution agreements, geographical expansion, development of new products, , and partnerships to sustain in the competition. For instance, in April 2021, Applied Spectral Imaging and Kromatid signed a strategic partnership agreement to be the exclusive seller of Kromatid’sPinpoint fluorescence in situ hybridization (PPF) probes and assay services. Some of the prominent players in the in situ hybridization market include:

  • Leica Biosystems Nussloch GmbH

  • Merck KGaA

  • Thermo Fisher Scientific

  • Agilent Technologies


  • PerkinElmer, Inc.

  • NeoGenomics Laboratories, Inc.

  • Bio-Rad Laboratories, Inc.

  • Oxford Gene Technology

  • Advanced Cell Diagnostics, Inc.

In Situ Hybridization Market Report Scope

Report Attribute


Market size value in 2021

USD 1,453.5 million

Revenue forecast in 2028

USD 2.6 billion

Growth rate

CAGR of 8.9% from 2021 to 2028

Base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, probe type, application, product, region, end-IVDuse, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; Italy; Spain; France; Japan; China; India; South Korea; Australia; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

PerkinElmer, Inc.; Thermo Fisher Scientific Inc.; BioView; Agilent Technologies; Merck KGaA; Bio-Rad Laboratories, Inc.; Oxford Gene Technology; Leica BiosystemsNussloch GmbH; NeoGenomics Laboratories; Advanced Cell Diagnostics, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global in situ hybridization market report on the basis of, technology, product, probe type, application, end-use, and region:

  • Technology Outlook (Revenue, USD Million, 2017 - 2028)

    • Fluorescent In Situ Hybridization (FISH)

    • Chromogenic In Situ Hybridization (CISH)

  • Probe Type Outlook (Revenue, USD Million, 2017 - 2028)

    • DNA

    • RNA

  • Product Outlook (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Kits & Probes

    • Software

    • Services

  • Application Outlook (Revenue, USD Million, 2017 - 2028)

    • Cancer

    • Cytogenetics

    • Developmental Biology

    • Infectious Diseases

    • Others

  • End-use Outlook (Revenue, USD Million, 2017 - 2028)

    • Hospitals & Diagnostic Laboratories

    • CROs

    • Academic& Research Institutes

    • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon